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We describe the epidemiology of invasive meningo-
coccal disease in South Africa from August 1999 through
July 2002, as reported to a laboratory-based surveillance
system. Neisseria meningitidis isolates were further char-
acterized. In total, 854 cases of laboratory-confirmed dis-
ease were reported, with an annual incidence rate of
0.64/100,000 population. Incidence was highest in infants
<1 year of age. Serogroup B caused 41% of cases;
serogroup A, 23%; serogroup Y, 21%; serogroup C, 8%;
and serogroup W135, 5%. Serogroup B was the predomi-
nant serogroup in Western Cape Province, and disease
rates remained stable. Serogroup A was most prevalent in
Gauteng Province and increased over the 3 years. On
pulsed-field gel electrophoresis analysis, serogroup A
strains showed clonality, and serogroup B demonstrated
considerable diversity. Selected isolates of serogroup A
belonged to sequence type (ST)-1 (subgroup I/II) complex,
serogroup B to ST-32/electrophoretic type (ET)-5 complex,
and serogroup W135 to ST-11/ET-37 complex.
D
espite progress in our understanding of the epidemiol-
ogy of meningococcal disease, infection with
Neisseria meningitidis continues to be a serious public
health concern worldwide. Although occurring predomi-
nantly as sporadic disease with seasonal variation in most
parts of the world, the highest burden of meningococcal
disease occurs in the “meningitis belt” of sub-Saharan
Africa, where epidemics are observed regularly (1).
Historically these epidemics were associated with
serogroup Aand, to a lesser extent, serogroup C. However,
serogroup W135 has recently emerged as a cause of epi-
demic disease in Africa (2,3), after outbreaks in 2000 and
2001 in Saudi Arabia during the annual Hajj pilgrimage to
Mecca (4–6). Epidemics of meningococcal disease have
occurred in Africa outside the meningitis  belt (7,8).
Meningococcal disease associated with epidemics in
Africa is generally caused by a limited number of geneti-
cally defined clonal groups (9,10). The 3 serogroup Apan-
demic waves reaching the African meningitis belt were
caused by clones of subgroup III (11,12), and the recent
outbreaks of W135 in West Africa were caused by strains
belonging to the ET-37 complex (3,13).
In South Africa, meningococcal disease (a clinically
reportable condition since 1920) is endemic, with seasonal
increases during the winter months (14,15). Incidence
rates, as determined by clinical notifications to the
Department of Health, have been steadily decreasing from
≈5–10/100,000 (1945–1975) to <2/100,000 (1992–1997)
(16–18). Upsurges of disease with a periodicity of several
years have been noted (17). During the late 1970s, the epi-
demiology changed from a preponderance of disease due
to serogroup Ain young adult black men on the gold mines
in the Southern Transvaal (now Gauteng) Province, to
mostly serogroup B disease affecting young mixed-race
infants in Western Cape Province (15,16). Serogroup B has
caused peaks in disease rates in Western Cape in 1979
(9,19–21) and again in 1988. Although predominant in
Western Cape, serogroup B also caused cases in
Johannesburg, Gauteng, during 1980–1982, where >60%
of meningococcal disease in children was due to serogroup
B (22). Increases in serogroup A disease in Gauteng were
described in the 1980s and 1996 (18,23,24).
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Materials and Methods
Case Definition
National laboratory-based surveillance for invasive
disease caused by N. meningitidis is performed by the
Respiratory and Meningeal Pathogens Research Unit
(RMPRU) at the National Institute for Communicable
Diseases (a branch of the National Health Laboratory
Service) in Johannesburg, South Africa. Cases were
defined as isolation of N. meningitidis from normally ster-
ile body fluid specimens (blood, cerebrospinal fluid [CSF],
or both) from patients in August 1999 through July 2002.
Isolates were submitted voluntarily to RMPRU by ≈100
laboratories nationally. Laboratories were encouraged to
submit case reports of laboratory-confirmed disease even
if viable isolates were no longer available for submission.
(Some isolates lost viability during transport to the central
laboratory.) Annual audits were performed to ascertain
missed cases, and these were included on the database (but
were without viable isolates for further testing at the cen-
tral laboratory). These audits identified 118 cases not
reported, to reach a final total of 557 cases from the
provinces/laboratories audited, which suggests that
≈70%–80% of laboratory-confirmed cases were reported
to the surveillance system.
Serogrouping
Serogroup was determined for 615 isolates by using
latex slide agglutination with monoclonal antiserum to
capsular polysaccharides A, B, C, X, Y, Z, and W135
(Murex Biotech Limited, Dartford, England, United
Kingdom). Strains that did not react with these antisera
were sent to the World Health Organization Collaborating
Center for Reference and Research on Meningococci,
Oslo, Norway, for serogrouping.
Pulsed-Field Gel Electrophoresis (PFGE)
PFGE was performed on 573 viable isolates of
serogroup A, B, C, W135, and Y meningococci by using a
method adapted from Popovic et al. (25). PFGE restriction
profiles were analyzed with the GelCompar version 4.1
software (Applied Maths, Kortrijk, Belgium).
Dendrograms were created by using the unweighted pair
group method with arithmetic averages. Analysis of the
banding patterns was performed with the Dice coefficient
and a position tolerance of 1.5% for the band migration
distance. A PFGE cluster was defined as >3 isolates shar-
ing >80% similarity on the dendrogram (25,26).
Multi-Locus Sequence Typing (MLST)
MLST was performed on 46 isolates as described by
Maiden et al. (27). We made use of the Neisseria MLST
website (http://pubmlst.org/neisseria/) sited at the
University of Oxford (28).
Statistical Analysis
Incidence rates were calculated on the basis of the
number of cases reported during the 12-month periods
from August 1 through July 31 of the following year,
divided by mid-year population estimates for years 2000,
2001, and 2002, respectively, obtained from the South
African Health Information Systems Programme. The χ2
test for linear trend using EpiInfo 6 (version 6.04d; Centers
for Disease Control and Prevention, Atlanta, Georgia,
USA) was used to assess statistical significance of the




From August 1999 through July 2002, 854 cases of
invasive meningococcal disease were reported; age was
known for 756 (88%) patients. Most cases (645, 76%)
were diagnosed from positive culture of CSF specimens
(with or without positive cultures from blood specimens);
the other 209 (24%) were positive on blood culture alone.
The incidence rates of disease reported to the network
increased from 0.52 per 100,000 persons in 1999–2000, to
0.62 in 2000–2001, and 0.77 in 2001–2002 (p<0.001).
Western Cape Province was responsible for 37% of cases
reported nationally, and Gauteng Province was responsible
for 41% of cases reported nationally (Figure 1). In Western
Cape Province, disease rates remained relatively stable;
rates of reported disease were calculated as 2.87/100,000,
1.91/100,000, and 2.27/100,000 for each 12-month period,
respectively (p = 0.068) (Figure 2). The incidence rates in
Gauteng Province increased from 0.54/100,000 in the first
year to 1.42/100,000 and 1.99/100,000 in the subsequent 2
years (p<0.001) (Figure 3). Seasonal variation was
observed; the highest number of cases was reported in July
to October (winter and spring) (data not shown). The high-
est age-specific incidence of meningococcal disease was
seen in infants <1 year of age; the average incidence rate
was 6.7/100,000. One hundred eighty-two (24%) of
patients were infants <1 year of age, 116 (15%) were chil-
dren 2–4 years of age, and 127 (17%) were young adults
15–24 years of age.
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Of the 854 cases of laboratory-confirmed meningo-
coccal disease reported to the surveillance network, 615
(72%) had viable isolates available for serogrouping; 453
(74%) of these were isolated from CSF and 162 (26%)
from blood culture alone. Serogrouping of the viable
meningococcal isolates showed the following: serogroup
B, 251 isolates (41%); A, 142 (23%); Y, 130 (21%); C, 50
(8%); W135, 31 (5%); X, 8 (1%); Z, 2 (<1%); and 29E, 1
(<1%) (Table 1).
Seventy percent (175/251) of serogroup B disease was
reported from Western Cape Province, where the number
of cases decreased progressively from 81 in the first year
(1999–2000) to 38 (in the third year, 2001–2002) (Table 1)
and incidence decreased from 1.85/100,000 to 0.82,
respectively (p<0.001) (Figure 2). Eighty-five percent
(121/142) of serogroup A disease came from Gauteng
Province, and the annual number of cases increased from 9
to 78 during the study period (Table 1). The incidence rate
increased from 0.11/100,000 in the first year to 0.86 in the
third year (p<0.001) (Figure 3). The proportion of disease
caused by serogroups C, W135, and Y remained stable
during the 3-year period (Table 1). Serogroup W135 was
most prevalent in Gauteng Province (19 [61%] of the 31
cases occurred there), and serogroup C was most prevalent
in Western Cape Province (28 [56%] of 50).
The age-specific proportion of disease in patients with
known age varied for serogroups. The highest proportion
of serogroup A (38 [33%] of 114) and C (10 [20%] of 50)
disease occurred in the 15- to 24-year age group; the high-
est proportion of disease caused by serogroup B (70 [29%]
of 238) and Y (42 [38%] of 112) was in infants <1 year of
age. Serogroup W135 was found in equal proportion in the
<1-year age group (6 [23%] of 26) and 15–24 age group (7
[27%] of 26). Incidence rates for the most common
serogroups (A, B, and Y) for the last year of surveillance
showed the highest rates of disease in children <1 year of
age (Figure 4). Serogroup Ahad the lowest rates of disease
for infants of the 3 serogroups and also had a second small
peak for young adults. These trends were similar in the
previous 2 years.
Of 615 N. meningitidis isolates serogrouped, 573
(93%) isolates were characterized by PFGE. Forty-six of
these isolates were selected for MLST (Table 2).
Molecular Epidemiology
Serogroup A
PFGE analysis of 123 serogroup A isolates showed a
highly clonal population structure with a large cluster
(cluster A-1) representing 89% (109/123) (Figure 5, Table
2). The proportion of serogroup A meningococcal disease
associated with strains of cluster A-1 increased from 38%
(5/13) in 1999–2000 to 97% (70/72) in 2001–2002
(p<0.001). Most isolates from this cluster (101/109, 93%)
originated from Gauteng Province and increased from
56% (5/9) in the first year, to 97% (30/31 and 66/68,
respectively) in the second and third years (p<0.001).
MLST analysis of 12 isolates from cluster A-1 showed
identical allelic profiles belonging to sequence type (ST)-
1, the prototype ST for the ST-1 (subgroup I/II) complex
(Table 2). MLST analysis of 4 isolates outside of cluster A-
1 yielded strains belonging to ST-7 (n = 2), ST-254 (n = 1),
and ST-175 (n = 1) (Table 2).
Serogroup B
In total, 242 serogroup B N. meningitidis isolates were
analyzed by PFGE. Five distinct clusters were observed,
with a predominant cluster (cluster B-1) consisting of 38%
(91/242) of the isolates (Figure 6). The proportion of iso-
lates within this cluster was 36%, 36%, and 43% for each
12-month period, respectively (p = 0.369). Eighty-two
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 2, February 2007 275
Meningococcal Disease in South Africa, 1999–2002
Figure 1. Map of South Africa with estimated provincial popula-
tions in 2002 (45.5 million population). Values are in millions. 
Figure 2. Incidence rates for all reported and serogroup B–
confirmed meningococcal disease by year in Western Cape
Province. *χ2 test for trend. percent (75/91) of the isolates from this cluster were from
the Western Cape, and the proportion of these strains in
this province remained stable over time. Five isolates from
this cluster were selected for MLST analysis. Four isolates
were ST-33 (Table 2). One isolate had a novel allele at the
fumC locus (28); a new ST (ST-4239, still part of ST-32
complex) was assigned to this isolate.
The second largest cluster (cluster B-2) comprised
12% (29/242) of the total number of isolates characterized.
Three isolates belonged to ST-41/44 lineage III, 2 of which
were ST-154. The third isolate had a novel allele at the
abcZ locus and was assigned ST-4242.
Clusters B-3, B-4, and B-5 comprised 9.5% (23/242),
7% (17), and 6% (14) of all serogroup B isolates, respec-
tively. The remaining isolates were clustered into small
groups or were unrelated.
Serogroup C
PFGE of the 49 serogroup C meningococcal isolates
showed 3 main clusters (clusters C-1, C-2, and C-3) (Table
2). Cluster C-1 comprised 31% (15/49) of the total number
of serogroup C isolates and showed no particular concen-
tration by province. Two isolates from this cluster were
ST-11 (Table 2).
Isolates belonging to clusters C-2 and C-3 each made
up 18% (9/49) of the total number of isolates characterized
(Table 2). Isolates from both clusters came exclusively
from Western Cape (18/18 isolates). MLST of 2 strains
from each cluster identified ST-865 in cluster C-2 (an ST
not associated with any broader STcomplex), and ST-33 in
RESEARCH
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Figure 3. Incidence rates for all reported and serogroup A–
confirmed meningococcal disease by year in Gauteng Province.
*χ2 test for trend.cluster C-3 (Table 2). The remaining isolates all showed
unrelated PFGE patterns.
Serogroup W135
Of the 31 serogroup W135 meningococci isolates ana-
lyzed by PFGE, a distinct cluster (cluster W-1) of isolates
comprising 23 (74%) of 31 isolates was found (Table 2).
Seventeen (74%) of cluster W-1 isolates came from
Gauteng Province. MLST analysis of 4 isolates from clus-
ter W-1 (2 isolates from Gauteng and 1 each from Western
Cape and KwaZulu Natal Provinces) showed they were
ST-11, the founder sequence type of the ST-11/elec-
trophoretic type (ET)-37 complex. Cluster W-2 comprised
3 isolates from 3 provinces, and MLST of 1 of the isolates
showed that it belonged to ST-4241 (ST-22 complex). The
remaining isolates were unrelated.
Serogroup Y
PFGE analysis of the 128 serogroup Y meningococcal
isolates showed 2 clusters (clusters Y-1 and Y-2; Table 2).
The predominant cluster (cluster Y-1) consisted of 92
(72%) isolates. Twenty-five (27%) isolates from cluster Y-
1 came from Free State Province, 27 (29%) from Gauteng
Province, and 15 (16%) from Western Cape Province.
MLSTof 6 isolates from this cluster showed that they were
ST-175 (Table 2).
Asecond cluster, cluster Y-2, comprised 15% (19/128)
of isolates (Table 2). Fifty-three percent (10/19) of these
isolates were from Gauteng Province. MLST analysis of 3
isolates showed 2 STs, 1 identified as ST-23 (2 isolates),
with the third possessing a novel allele at the abcZ locus
(assigned new ST-4245). The remaining isolates (17/128,
13%) demonstrated groups of 2, 3, or 5 isolates; and 4
unrelated isolates. MLST analysis of 1 of these isolates
showed that it belonged to ST-175.
Discussion
The endemic nature and low incidence rates of
meningococcal disease in the study period confirm an
epidemiology related more closely to industrialized coun-
tries (29,30) than to countries of the African meningitis
belt. Rates of national disease, as calculated by clinical
notifications, ranged between 1 and 2/100,000 from 1992
to 1997 (18) and are similar to those calculated in our
study. Although laboratory-based surveillance in South
Africa clearly underestimates the impact of disease,
audits indicate that more than two thirds of laboratory-
confirmed disease were reported, and we believe our data
are representative enough to reflect general trends of
disease.
Overall, the age group at greatest risk for disease was
children <1 year of age, although there were some differ-
ences by serogroup. Serogroup B has been previously
described to occur predominantly in infants (15,22,30);
serogroup A disease also causes disease in adults
(15,22,24). Serogroup Ydisease occurring in older patients
has been documented (30), but this was not observed in
our study.
The high proportion of laboratory-confirmed cases
from Gauteng and Western Cape Provinces could reflect
better reporting by laboratories in these areas. These 2
provinces also had the most clinical notifications, which
would be less reliant on laboratory facilities, to the
Department of Health since the 1970s (18). Other parts of
South Africa were noted to have much lower rates of dis-
ease (15). Although access to medical care may influence
rates by province, the fulminant and distinctive clinical
manifestations of meningococcal disease allow for ade-
quate clinical reporting from health facilities. True envi-
ronmental, socioeconomic, or host-related factors may be
resulting in higher disease rates in these provinces.
Climate varies between areas in the country: Western Cape
has a Mediterranean climate with wet winters and hot, dry
summers; Gauteng lies on a plateau and has a temperate
climate with summer rainfall; and KwaZulu Natal has a
predominantly subtropical climate (31).
The incidence rate of reported meningococcal disease
increased from 1999 to 2002, and serogroup A, most
prevalent in Gauteng Province, was the only serogroup of
viable isolates to increase significantly. Cyclical changes
in meningococcal disease occurring every 8 to 10 years
have been noted in this province (18). Case ascertainment
of prospectively reported cases may have increased as the
surveillance became more established and as audits high-
lighted nonreporting from certain laboratories that were
subsequently included in the surveillance. Serogroup A
meningococci are associated with most outbreaks through-
out the African meningitis belt (1). No discrete outbreaks
were identified associated with serogroup Adisease during
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Figure 4. Annual age-specific incidence rates for confirmed
serogroup A, B, and Y meningococcal disease in South Africa, as
reported from August 2001 through July 2002. the study period; however, unrecognized clusters may have
occurred.
The increase in the number of cases of serogroup A
reported from Gauteng Province was associated specifical-
ly with strains belonging to a distinct cluster identified by
PFGE. Selected isolates from this cluster were confirmed
as belonging to ST-1 (subgroup I/II) complex. These
strains have caused epidemics worldwide (11,32,33). In
South Africa, subgroup I strains were first identified in
1968 (1 isolate) (11,32) and from 1976 through 1983 (41
isolates) (32). In 1996, 49.5% (55/111) of isolates analyzed
from an outbreak in South Africa were identified as
serogroup A belonging to subgroup I; 13.5% (15/111)
belonged to subgroup III (34). MLST analysis of 1 of these
subgroup III isolates showed it was ST-5 (data not shown).
Recently, in the meningitis belt, ST-5 (predominant in
1988–2001) has been replaced by ST-7 in 2002, and no ST-
1 strains were identified (35). In our study, 2 isolates ana-
lyzed by MLST were confirmed as ST-7, which suggests
that the third pandemic wave from People’s Republic of
China may have reached South Africa (12,35). The pre-
dominant serogroup A strain causing disease in South
Africa, however, was not the same strain as that in the
meningitis belt.
The high proportion of sporadic serogroup B disease
in the Western Cape has been well described since the late
1970s (15,19,36). Serogroup B is rarely reported from
other countries in Africa, and our data reflect an epidemi-
ology for this serogroup more consistent with industrial-
ized countries (9,37). The proportion of serogroup B
meningococcal disease nationally decreased significantly,
mostly due to a decrease in the number of viable serogroup
B isolates identified from the Western Cape. This province
had no change in total reported disease rates. By PFGE this
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typical of sporadic serogroup B disease worldwide (30,38)
and previously documented in the Western Cape (39).
Complexes ST-32/ET-5 and ST-41/44/lineage III have
been associated with outbreaks worldwide (9,37). These
strains have been causing disease in the Western Cape
since the late 1970s (9,21,39).
Serogroup Y accounts for approximately one third of
all invasive meningococcal disease in the United States
(30), but it has been rare in the African meningitis belt
(1,35). A serogroup Y isolate with ST-175 has been previ-
ously described from The Gambia in 1988
(www.pubmlst.org/neisseria), and recently ST-23 and ST-
2880 have been identified in the meningitis belt (35). Our
data thus represent the first evidence of a major role for
serogroup Y disease in Africa.
Serogroup C disease associated with sporadic disease
and occasional outbreaks occurs in both industrialized and
developing nations (1,30). Complexes ST-11/ET-37 and
ST-32/ET-5 are hypervirulent meningococci reported
worldwide (9,37). In South Africa, a community-based
outbreak caused by strains of the ST-11/ET-37 complex
was observed in 2003 (40). ST-865 strains have been
reported to cause disease in Taiwan, Spain, and the United
States (www.pubmlst.org/neisseria), but these were associ-
ated with nongroupable and non–serogroup C isolates. To
our knowledge, we document the first serogroup C strain
of ST-865.
Serogroup W135, associated with little disease world-
wide (1,13), represented a small proportion of disease in
our surveillance. Complex ST-11/ET-37 was responsible
for outbreaks in 2000 and 2001 associated with the annual
Hajj pilgrimage (4,6,13) and for outbreaks in Burkina Faso
in 2001 (2). PFGE comparison of isolates from a predom-
inant cluster in South Africa with an isolate from the Hajj
outbreak showed that they were related (data not shown).
Strains of ET-37 had been in South Africa in 1986 and
1990 (13), and this clone may have been reintroduced dur-
ing the Hajj outbreak.
In conclusion, we identified sporadic and seasonal
meningococcal disease in South Africa during the study
period, caused in part by an increasing number of cases
due to a clone of serogroup A in Gauteng Province.
Diverse strains of serogroup B were responsible for stable
prevalence of disease in Western Cape Province.
Nationally, 21% of meningococcal disease was due to
serogroup Y. Continued surveillance will provide valuable
information for the development of public health strategies
to minimize the risk for outbreaks in South Africa and
neighboring countries.
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Figure 5. Pulsed-field gel electrophoresis dendrogram indicating
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